Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
CNSY
Cerenome, Inc.
CAPPED RATING
Cerenome, Inc. (CNSY) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
B
Factor Score
3.4
/ 5.0
Growth
B-
Factor Score
3.0
/ 5.0
Profitability
D+
Factor Score
1.5
/ 5.0
Momentum
F
Factor Score
0.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.3
EV / EBITDA
0.1
Rev Growth YoY
-70.4%
Gross Margin
N/M
Price Return 3M
-81.6%
Price Return 12M
-95.0%
Catalyst Signal
0.00
Market Cap
$5.1M
TTM Revenue
$4.2M
Price / Sales
1.2
ROE
N/M
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.4) | B- (3.0) | D+ (1.5) | F (0.5) | C+ (2.6) | C (2.2) |
| 2026-11-04 | B- (3.0) | B- (3.0) | D+ (1.6) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | B- (3.0) | B- (2.9) | D+ (1.5) | D- (0.7) | C+ (2.7) | C (2.2) |
| 2026-10-21 | B- (3.0) | B- (2.9) | D+ (1.5) | F (0.6) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | B- (3.0) | B- (2.9) | D+ (1.5) | D- (0.7) | C+ (2.6) | C (2.2) |
Page
1
of
3